ArticleEuropean journal of radiology open2025
Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of pancreatic ductal adenocarcinoma.
Article in European journal of radiology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to identify preoperative computed tomography (CT) imaging features for predicting early recurrence after upfront pancreatoduodenectomy of pancreatic ductal adenocarcinoma (PDAC), and to assess the diagnostic performance and prognostic relevance of their combination. Methods: This study retrospectively included PDAC patients who underwent pancreatoduodenectomy and preoperative pancreatic CT between January 2016 and December 2023. Early recurrence is defined based on imaging evidence or pathology within 12 months after surgery. Significant imaging features for early recurrence were identified using univariate and multivariate analyses. Disease-free survival (DFS) and overall survival (OS) were analyzed in relation to these significant imaging features. Results: A total of 149 patients were evaluated (median age: 67 years; interquartile range: 41-89 years; 82 men), among whom 70 (47.0 %) experienced early recurrence. Rim enhancement, tumor necrosis, peripancreatic tumor infiltration, and suspicious metastatic lymph nodes, were independently associated with early recurrence. When any two or more of these four significant imaging features were combined, the specificity was 86.1 % (68/79) and the sensitivity was 88.6 % (60/70). DFS and OS were significantly worse in PDAC patients with two or more of these features compared to those with none or only one (all log-rank Conclusion: A combination of two or more imaging features such as rim enhancement, tumor necrosis, peripancreatic tumor infiltration, and suspicious metastatic lymph nodes, could be used as a prognostic imaging marker for early recurrence, demonstrating effective diagnostic performance and an association with DFS and OS after pancreatoduodenectomy of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.